ICON: Eosinophil Disorders

World Allergy Organization Journal

Gerald J Gleich^1,16  Peter F Weller^1,12  Peter Vandenberghe^1,19  Karl Sotlar^1,15  Hans-Uwe Simon³  Marc E Rothenberg^1,11  Florence Roufosse^1,10  Andreas Reiter^1,13  Kenji Matsumoto⁶  Georgia Metzgeroth^1,13  Kristin M Leiferman¹  Hans-Peter Horny⁸  Andrzej Hellmann^1,15  Torsten Haferlach⁹  Jason Gotlib^1,14  Joseph H Butterfield^1,17  Bruce S Bochner^1,18  Michel Arock⁷  Lanny J Rosenwasser⁴  Amy D Klion⁵  Peter Valent² 

[1] Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT;Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria, Wahringer Gurtel 18-20, Wien A-1090 Austria;Institute of Pharmacology, University of Bern, Bern, Switzerland;Children's Mercy Hospital, Kansas City, MO;Eosinophil Pathology Unit, Laboratory of Parasitic Diseases, NIH/NIAID, Bethesda, MD;Department of Allergy and Immunology, National Research Institute for Children's Health and Development, Tokyo, Japan;LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France;Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany;MLL Münchner Leukämielabor, Munich, Germany;Department of Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium;Division of Allergy and Immunology, Cincinnati Children's Hospital, Medical Center, Cincinnati, OH;Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany;Division of Hematology, Stanford Cancer Center, Stanford, CA;Department of Hematology, Medical University School of Gdansk, Gdańsk, Poland;Department of Medicine, University of Utah Health Sciences Center, Salt Lake City, UT;Division of Allergic Diseases, Mayo Clinic, Rochester, MN;Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD;Center for Human Genetics, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium

关键词: classification;    global consensus;    hypereosinophilic syndrome (HES);    eosinophil disorders;   

Others  :  1137669
DOI  :  10.1097/WOX.0b013e31827f4192

【 授权许可】

   
2012 World Allergy Organization; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hardy WR, Anderson RE: The hypereosinophilic syndromes. Ann Intern Med 1968, 68:1220-1229.
• [2]Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975, 54:1-27.
• [3]Weller PF, Bubley GJ: The idiopathic hypereosinophilic syndrome. Blood 1994, 83:2759-2779.
• [4]Roufosse F, Cogan E, Goldman M: The hypereosinophilic syndrome revisited. Annu Rev Med 2003, 54:169-184.
• [5]Wilkins HJ, Crane MM, Copeland K, Williams WV: Hypereosinophilic syndrome: an update. Am J Hematol 2005, 80:148-157.
• [6]Simon D, Simon HU: Eosinophilic disorders. J Allergy Clin Immunol 2007, 119:1291-1300.
• [7]Simon HU, Rothenberg ME, Bochner BS, et al.: Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:45-49.
• [8]Valent P: Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 2009, 23:157-165.
• [9]Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, et al.: Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012, 130:607-612.
• [10]Bain BJ, Pierre R, Imbert M, Vardiman JW, Brunning RD, et al.: Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Volume 1. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon, France: IARC Press; 2001::29-31.
• [11]Bain BJ, Gilliland DG, Vardiman JW, Horny HP: Chronic eosinophilic leukemia, not otherwise specified. In World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Volume 2. Edited by Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. Lyon, France: IARC Press; 2008::51-53.
• [12]Bain BJ, Gilliland DG, Horny HP, Vardiman JW: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Volume 2. Edited by Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. Lyon, France: IARC Press; 2008::68-73.
• [13]Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14-22.
• [14]Vandenberghe P, Wlodarska I, Michaux L, et al.: Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004, 18:734-742.
• [15]Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C: The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2008, 87:1-10.
• [16]Cross NC, Reiter A: Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008, 119:199-206.
• [17]Gotlib J, Cools J: Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008, 22:1999-2010.
• [18]Tefferi A: Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. JCellMol Med 2009, 13:215-237.
• [19]Kay AB: The eosinophil in infection diseases. J Infect Dis 1974, 129:606-613.
• [20]Capron M: Eosinophils and parasites. Ann Parasitol Hum Comp 1991, 66:41-45.
• [21]Walsh SA, Creamer D: Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 2011, 36:6-11.
• [22]Kargili A, Bavbek N, Kaya A, Kosxar A, Karaaslan Y: Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases. Rheumatol Int 2004, 24:321-324.
• [23]Tefferi A, Patnaik MM, Pardanani A: Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006, 133:468-492.
• [24]Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, et al.: Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1987, 1:643-647.
• [25]Kato M, Kephart GM, Talley NJ, et al.: Eosinophil infiltration and degranulation in normal human tissue. Anat Record 1998, 252:418-425.
• [26]Noguchi H, Kephart GM, Colby TV, Gleich GJ: Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol 1992, 140:521-528.
• [27]Nutman TB: Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin North Am 2007, 27:529-549.
• [28]Gotlib J, Cross NC, Gilliland DG: Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 2006, 19:535-569.
• [29]Bain BJ, Fletcher SH: Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007, 27:377-388.
• [30]Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, et al.: Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012, 5:157-176.
• [31]Wimazal F, Germing U, Kundi M, Noesslinger T, Blum S, et al.: Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer 2010, 116:2372-2381.
• [32]Pardanani A, Reeder T, Li CY, Tefferi A: Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003, 27:883-885.
• [33]Böhm A, Födinger M, Wimazal F, Haas OA, Mayerhofer M, et al.: Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 2007, 120:192-199.
• [34]Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, et al.: Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114:3769-3772.
• [35]Takai K, Sanada M: Hypereosinophilic syndrome evolving to acute lymphoblastic leukemia. Int J Hematol 1991, 54:231-239.
• [36]Scales JW, McMichael A: Persistent peripheral eosinophilia and cutaneous non-Hodgkin's lymphoma: a case report and review of the literature. Cutis 2001, 67:67-70.
• [37]Roufosse F, Cogan E, Goldman M: Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007, 27:389-413.
• [38]Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, et al.: Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13) (p11;q12) myeloproliferative syndrome. Blood 1998, 92:1735-1742.
• [39]Lowe D, Jorizzo J, Hutt MS: Tumour-associated eosinophilia: a review. J Clin Pathol 1981, 34:1343-1348.
• [40]Hogan SP, Rosenberg HF, Moqbel R, et al.: Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008, 38:709-750.
• [41]Simon HU, Plötz SG, Dummer R, Blaser K: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999, 341:1112-1120.
• [42]Roufosse F, Schandené L, Sibille C, Willard-Gallo K, Kennes B, et al.: Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000, 109:540-548.
• [43]Freymond N, Kahn JE, Legrand F, Renneville A, Cordier JF, et al.: Clonal expansion of T cells in patients with eosinophilic lung disease. Allergy 2011, 66:1506-1508.
• [44]Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, O'Connell EJ, et al.: Episodic angioedema associated with eosinophilia. N Engl J Med 1984, 310:1621-1626.
• [45]Butterfield JH, Leiferman KM, Abrams J, et al.: Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 1992, 79:688-692.
• [46]Gross WL: Churg-Strauss syndrome: update on recent developments. Curr Opin Rheumatol 2002, 14:11-14.
• [47]Keogh KA, Specks U: Churg-Strauss syndrome. Semin Respir Crit Care Med 2006, 27:148-157.
• [48]Pagnoux C, Guillevin L: Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol 2010, 22:21-28.
• [49]Silver RM: Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1992, 4:851-856.
• [50]Kaufman LD, Krupp LB: Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1995, 7:560-567.
• [51]Belongia EA, Gleich GJ: The eosinophilia-myalgia syndrome revisited. J Rheumatol 1996, 23:1682-1685.
• [52]Crane MM, Chang CM, Kobayashi MG, Weller PF: Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010, 126:179-181.
• [53]Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, et al.: Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Hematol Oncol 2010, 28:93-97.
• [54]Gleich GJ: Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000, 105:651-663.
• [55]Ackerman SJ, Bochner BS: Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007, 27:357-375.
• [56]Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, et al.: Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989, 19:701-705.
• [57]Kita H, Weiler DA, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ: Release of granule proteins from eosinophils cultured with IL-5. J Immunol 1992, 149:629-635.
• [58]Yousefi S, Blaser K, Simon HU: Activation of signaling pathways and prevention of apoptosis by cytokines in eosinophils. Int Arch Allergy Immunol 1997, 112:9-12.
• [59]Kahn JE, Dutoit-Lefevre V, Duban-Deweer S, Chafey P, Pottiez G, et al.: Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. J Proteome Res 2011, 10:1468-1480.
• [60]Weller PF: Eicosanoids, cytokines and other mediators elaborated by eosinophils. In Eosinophils: Biological and Clinical Aspects. Edited by Makino S, Fukuda T. Boca Raton, FL: CRC Press; 1993:125-154.
• [61]Moqbel R, Levi-Schaffer F, Kay AB: Cytokine generation by eosinophils. J Allergy Clin Immunol 1994, 94:1183-1188.
• [62]Moqbel R, Ying S, Barkans J, et al.: Identification of messenger RNA for IL-4 in human eosinophils with granule localisation and release of the translated product. J Immunol 1995, 155:4939-4947.
• [63]Kay AB, Barata L, Meng Q, Durham SR, Ying S: Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol 1997, 113:196-199.
• [64]Walsh GM: Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci 1999, 36:453-496.
• [65]Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, et al.: Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 1989, 142:4428-4434.
• [66]Hamann KJ, Barker RL, Ten RM, Gleich GJ: The molecular biology of eosinophil granule proteins. Int Arch Allergy Appl Immunol 1991, 94:202-209.
• [67]Plager DA, Stuart S, Gleich GJ: Human eosinophil granule major basic protein and its novel homolog. Allergy 1998, 53:33-40.
• [68]Benezet-Mazuecos J, de la Fuente A, Marcos-Alberca P, Farre J: Loeffler endocarditis: what have we learned? Am J Hematol 2007, 82:861-862.
• [69]Ogbogu PU, Rosing DR, Horne MK III: Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007, 27:457-475.
• [70]Kleinfeldt T, Nienaber CA, Kische S, Akin I, Turan RG, et al.: Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol 2010, 99:419-427.
• [71]Jeong YJ, Kim KI, Seo IJ, Lee CH, Lee KN, et al.: Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics 2007, 27:617-637.
• [72]Simon D, Wardlaw A, Rothenberg ME: Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol 2010, 126:3-13.
• [73]Louis R, Sele J, Henket M, Cataldo D, Bettiol J, et al.: Sputum eosinophil count in a large population of patients with mild to moderate steroidnaïve asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 2002, 57:907-912.
• [74]Szefler SJ, Wenzel S, Brown R, et al.: Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012, 129:S9-23.
• [75]Leiferman KM, Gleich GJ, Peters MS: Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007, 27:415-441.
• [76]Zuo L, Rothenberg ME: Gastrointestinal eosinophilia. Immunol Allergy Clin North Am 2007, 27:443-455.
• [77]Lee J, Dierkhising R, Wu TT, Alexander J, Weiler C: Eosinophilic gastrointestinal disorders (EGID) with peripheral eosinophilia: a retrospective review at Mayo Clinic. Dig Dis Sci 2011, 56:3254-3261.
• [78]Klion A: Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 2009, 60:293-306.
• [79]Klion AD: How I treat hypereosinophilic syndromes. Blood 2009, 114:3736-3741.
• [80]Roufosse F, Weller P: Practical approach to the patient with marked hypereosinophilia. J Allergy Clin Immunol 2010, 126:39-44.
• [81]Rothenberg ME, Klion AD, Roufosse FE, et al.: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215-1228.
• [82]Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, et al.: Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:828-835.
• [83]Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
• [84]Cools J, DeAngelo DJ, Gotlib J, et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
• [85]Pardanani A, Reeder T, Porrata LF, et al.: Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003, 101:3391-3397.
• [86]Tefferi A: Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 2005, 114:52-60.
• [87]Reiter A, Grimwade D, Cross NC: Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica 2007, 92:1153-1158.
• [88]Metzgeroth G, Walz C, Erben P, et al.: Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008, 143:707-715.